Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Active, not recruiting · NCT03733535 · Registry updated 2025-08-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Active, not recruiting | Not applicable | 2025-08-11 | NCT03733535 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Dr. Grace Parraga | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre | London | Canada | 7 |